Search

Search results

399 results found

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.

Kimball, Alexandra B, Thrasivoulos Tzellos, Brian M Calimlim, Henrique D Teixeira, Ziqian Geng, and Martin M Okun. 2018. “Achieving Hidradenitis Suppurativa Response Score Is Associated With Significant Improvement in Clinical and Patient-Reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.”. Acta Dermato-Venereologica 98 (10): 932-37.

Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only : results of the 2005 Spring US National Psoriasis Foundation Survey.

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Revicki, Dennis A, Mary Kaye Willian, Alan Menter, Kenneth B Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Miriam Kimel, and Martin Okun. 2007. “Impact of Adalimumab Treatment on Patient-Reported Outcomes: Results from a Phase III Clinical Trial in Patients With Moderate to Severe Plaque Psoriasis.”. The Journal of Dermatological Treatment 18 (6): 341-50.

PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

Papp, Kim A, Bruce Strober, Matthias Augustin, Steve Calabro, Anil Londhe, Marc Chevrier, and PSOLAR investigators and Steering Committee. 2012. “PSOLAR: Design, Utility, and Preliminary Results of a Prospective, International, Disease-Based Registry of Patients With Psoriasis Who Are Receiving, or Are Candidates For, Conventional Systemic Treatments or Biologic Agents.”. Journal of Drugs in Dermatology : JDD 11 (10): 1210-7.